MiMedx to Cut $40M in Annual Costs, Takes $4M Q2 Charge
MiMedx plans to reduce annual operating expenses by $40 million through restructuring measures including elimination of its COO position, and will incur a one-time $4 million charge in Q2 2026. The initiative targets sluggish Wound Care recovery after January Medicare reimbursement cuts while sustaining Surgical investments.
1. Cost Reduction Initiative
MiMedx is implementing a restructuring program to trim operating expenses by approximately $40 million annually. A one-time restructuring charge of about $4 million is expected in Q2 2026 to facilitate these measures and improve long-term profitability.
2. Leadership Realignment
The company has eliminated the Chief Operating Officer role, with Ricci Whitlow departing after overseeing key regulatory audits and product launches. This change aims to streamline executive functions and allocate resources toward growth priorities.
3. Segment Performance Outlook
MiMedx will maintain investment in its expanding Surgical business while adjusting to a slower Wound Care market recovery following the January Medicare reimbursement reduction. Management plans to discuss first-quarter results and restructuring impacts during the upcoming April conference call.